A novel molecular scaffold has been synthesized and its synthesis and incorporation into new analogues of biologically active molecules will be discussed. A comparison of the inhibitory activity of these compounds to the known type-2 diabetes compound (sitagliptin) against dipeptidyl peptidase-4 (DPP-4) will be shown
Poor medication adherence is one of the leading causes of suboptimal glycaemic control in approximat...
The present invention is related to novel compounds of the general formula (A), their tautomeric for...
Starting from the lead isodaphnetin, a natural product inhibitor of DPP-4 discovered through a targe...
A novel molecular scaffold has been synthesized and its synthesis and incorporation into new analogu...
A novel molecular scaffold has been synthesized, and its synthesis and incorporation into new analog...
In our efforts to develop second generation DPP-4 inhibitors, we endeavored to identify distinct str...
A novel molecular scaffold has been synthesized, and its incorporation into new analogues of biologi...
Type II diabetes (T2DM) is considered one of the most prevalent metabolic disorders in the world. It...
Dipeptidyl peptidase IV (DPP-4) is a serine protease that plays a crucial role in glucose metabolism...
Type 2 diabetes mellitus is one of the most common diseases of the 21st century, caused by a sedenta...
AIM: To develop novel, potent, selective and orally active inhibitors of Dipeptidyl Peptidase IV wi...
Compounds that contain (R)-3-amino-4-(2,4,5-trifluorophenyl)butanoic acid substituted with bicyclic ...
Dipeptidyl peptidase-4 (DPP-4) inhibitors are accepted as a favorable class of agents for the treatm...
Objectives: Type-2 diabetes mellitus, caused by impaired secretion of insulin, is becoming one of th...
BACKGROUND: There has been great interest in determining whether natural products show biological ac...
Poor medication adherence is one of the leading causes of suboptimal glycaemic control in approximat...
The present invention is related to novel compounds of the general formula (A), their tautomeric for...
Starting from the lead isodaphnetin, a natural product inhibitor of DPP-4 discovered through a targe...
A novel molecular scaffold has been synthesized and its synthesis and incorporation into new analogu...
A novel molecular scaffold has been synthesized, and its synthesis and incorporation into new analog...
In our efforts to develop second generation DPP-4 inhibitors, we endeavored to identify distinct str...
A novel molecular scaffold has been synthesized, and its incorporation into new analogues of biologi...
Type II diabetes (T2DM) is considered one of the most prevalent metabolic disorders in the world. It...
Dipeptidyl peptidase IV (DPP-4) is a serine protease that plays a crucial role in glucose metabolism...
Type 2 diabetes mellitus is one of the most common diseases of the 21st century, caused by a sedenta...
AIM: To develop novel, potent, selective and orally active inhibitors of Dipeptidyl Peptidase IV wi...
Compounds that contain (R)-3-amino-4-(2,4,5-trifluorophenyl)butanoic acid substituted with bicyclic ...
Dipeptidyl peptidase-4 (DPP-4) inhibitors are accepted as a favorable class of agents for the treatm...
Objectives: Type-2 diabetes mellitus, caused by impaired secretion of insulin, is becoming one of th...
BACKGROUND: There has been great interest in determining whether natural products show biological ac...
Poor medication adherence is one of the leading causes of suboptimal glycaemic control in approximat...
The present invention is related to novel compounds of the general formula (A), their tautomeric for...
Starting from the lead isodaphnetin, a natural product inhibitor of DPP-4 discovered through a targe...
DOI
Add to ORKG